First Participant Dosed in HEART-STRONG Heart Failure Study

The first participant in our HEART-STRONG study — evaluating SGLT2 inhibition in heart failure with preserved ejection fraction — completed their baseline visit and first dose this week.

Heart failure with preserved ejection fraction affects millions of Americans and has historically had few treatment options. Studies like HEART-STRONG are changing that.

Enrollment continues for adults 40 and older with NYHA class II–IV symptoms and LVEF above 40%. Compensation up to $1,600 over 24 months.